Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Connecticut Children's Medical Center
mi
from
Hartford, CT
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Yale-New Haven Children's Hospital
mi
from
New Haven, CT
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Yale-New Haven Children's Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Nemours/Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Nemours/Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Holtz Children's Hospital
mi
from
Miami, FL
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Holtz Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Florida Hospital for Children
mi
from
Orlando, FL
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Florida Hospital for Children
mi
from
Orlando, FL
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Advocate Hope Children's Hospital
mi
from
Oak Lawn, IL
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Advocate Hope Children's Hospital
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
University of Maryland Hospital for Children
mi
from
Baltimore, MD
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
University of Maryland Hospital for Children
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Johns Hopkins Childrens Center
mi
from
Baltimore, MD
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Johns Hopkins Childrens Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
University of Massachusetts Memorial Children's Medical Center
mi
from
Worcester, MA
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
University of Massachusetts Memorial Children's Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
C S Mott Children's Hospital The University of Michigan
mi
from
Ann Arbor, MI
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
C S Mott Children's Hospital The University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Children's Mercy Hospital - Kansas City
mi
from
Kansas City, MO
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Children's Mercy Hospital - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
St. Louis Children's Hospital
mi
from
St. Louis, MO
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Children's Hospital at Montefiore
mi
from
Bronx, NY
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Cohen Children's Medical Center of New York
mi
from
New Hyde Park, NY
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Cohen Children's Medical Center of New York
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Doernbecher Children's Hospital
mi
from
Portland, OR
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Doernbecher Children's Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Monroe Carell Jr. Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Monroe Carell Jr. Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Medical City Children's Hospital
mi
from
Dallas, TX
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Medical City Children's Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Children's Medical Center of Dallas
mi
from
Dallas, TX
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Children's Medical Center of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated:  7/14/2015
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)
Sedation Management in Pediatric Patients With Acute Respiratory Failure
Status: Enrolling
Updated: 7/14/2015
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The First Therapeutic Intervention in Malignant Pleural Effusion Trial
TIME1: A 2 X 2 Factorial Trial to Assess Whether Non-steroidal Anti-inflammatory Analgesics and Small-bore Chest Tubes Are Less Painful Than Opiate Analgesics and Large-bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion.
Status: Enrolling
Updated:  7/16/2015
UC Davis Medical Center
mi
from
Sacramento, CA
The First Therapeutic Intervention in Malignant Pleural Effusion Trial
TIME1: A 2 X 2 Factorial Trial to Assess Whether Non-steroidal Anti-inflammatory Analgesics and Small-bore Chest Tubes Are Less Painful Than Opiate Analgesics and Large-bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion.
Status: Enrolling
Updated: 7/16/2015
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis
Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma
Status: Enrolling
Updated:  7/20/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis
Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma
Status: Enrolling
Updated: 7/20/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation
Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation
Status: Enrolling
Updated:  7/20/2015
Boston Med Ctr
mi
from
Boston, MA
Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation
Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation
Status: Enrolling
Updated: 7/20/2015
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Positive Airway Pressure for the Treatment of Asthma
Positive Airway Pressure for the Treatment of Asthma
Status: Enrolling
Updated:  7/20/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Positive Airway Pressure for the Treatment of Asthma
Positive Airway Pressure for the Treatment of Asthma
Status: Enrolling
Updated: 7/20/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Improving Management of Breathlessness in Patients With Lung Cancer
Improving Management of Breathlessness in Patients With Lung Cancer
Status: Enrolling
Updated:  7/20/2015
Massachusetts General Hospital
mi
from
Boston, MA
Improving Management of Breathlessness in Patients With Lung Cancer
Improving Management of Breathlessness in Patients With Lung Cancer
Status: Enrolling
Updated: 7/20/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1245.25.10061 Boehringer Ingelheim Investigational Site
mi
from
Riverside, CA
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1245.25.10061 Boehringer Ingelheim Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1222.51.01078 Boehringer Ingelheim Investigational Site
mi
from
Edina, MN
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1222.51.01078 Boehringer Ingelheim Investigational Site
mi
from
Edina, MN
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1237.15.01511 Boehringer Ingelheim Investigational Site
mi
from
St. Charles, MO
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1237.15.01511 Boehringer Ingelheim Investigational Site
mi
from
St. Charles, MO
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1268.17.01028 Boehringer Ingelheim Investigational Site
mi
from
New Braunfels, TX
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1268.17.01028 Boehringer Ingelheim Investigational Site
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated:  7/20/2015
1245.25.10182 Boehringer Ingelheim Investigational Site
mi
from
Morgantown, WV
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Status: Enrolling
Updated: 7/20/2015
1245.25.10182 Boehringer Ingelheim Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials